Skip to main content
Home
language-selector-globe Singapore | en

Choose Location

  • International
  • Americas
  • Europe
  • Middle East & Africa
  • Asia Pacific
  • Novartis Foundation | en
  • Sandoz | en
  • Global | en
  • Argentina | es
  • Mexico | es
  • United States | en
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Venezuela | es
  • Russia | ru
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Latvia | lv
  • Czech Republic | en
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Italy | it
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • South Africa | en
  • Turkey | tr
  • Denmark | da
  • Egypt | en
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Korea | ko
  • Singapore | en
  • Taiwan | zh
  • Japan | ja
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en

Language & Country Selector for Mobile

language-selector-globe Singapore

Choose Location

International Americas Europe Middle East & Africa Asia Pacific
  • Argentina | es
  • Russia | ru
  • Lithuania | lt
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Sandoz | en
  • Korea | ko
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Latvia | lv
  • Japan | ja
  • Australia | en
  • Czech Republic | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Denmark | da
  • Italy | it
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Venezuela | es
    • About
      • Novartis in Singapore
      • Strategy
      • Diversity and Inclusion
      • People and Culture
      • Products
      • Contact
      About
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Education and Awareness
      • Patient resources
      • Adverse Event Reporting
      Patients and Caregivers
    • Healthcare Professionals
      • Healthcare professional country resource
      • Products
      • Adverse Event Reporting
      • Novartis Clinical Trials
      Healthcare Professionals
    • ESG
      • Ethical Behavior
        • Code of Ethics
        • SpeakUp
      • Ethics, Risk and Compliance
      • Access
      • Environmental Sustainability
      • Global Health
    • News
      • News Archive
      • Stories
      • Contacts
      News
    • Careers
      • Career Search
      • Meet the teams
      • Learning and Development
      • Personal Growth
      • Early Talent
      • How We Work
      • Well-being
      • Diversity and Inclusion
      • Career Programs
      • Awards and Recognition
      Careers
    • Coronavirus
      Coronavirus
    Home

ATECTURA

Indacaterol acetate/mometasone furoate
Package Insert (PDF 851.06 KB)
Pharma
  • Print
  • PDF

Novartis Singapore

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Product Portfolio
Footer Bottom
© 2022 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Web Accessibility
  • Cookie Settings
  • Site Map
Novartis Site Directory
This site is intended for an audience in Singapore.